You searched for "AMN"
7th Anterior Segment Meeting
8 November 2024
A day of ophthalmic education with a range of interesting talks focusing on topics within Corneal, Oculoplastic, Glaucoma and Debates.Chairs: Mr Mario Saldanha & Mrs Anjana Haridas | Singleton Hospital) & Mrs. Anjana Haridas -University of Wales
AI breakthrough brings geographic atrophy treatment a step closer
20 September 2021
A team led by Dr Konstantinos Balaskas at Moorfields Eye Hospital Reading Centre has developed a fully automated, deep-learning model (algorithm) that can detect and quantify geographic atrophy using standard optical coherence tomography (OCT) scans.
Eye Capacity: clinical need should drive ophthalmic service provision
1 February 2014
| Rod McNeil
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...
How many injections in nAMD: ranibizumab vs. aflibercept
1 April 2017
| Eulee Seow
|
EYE - Vitreo-Retinal
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
Macular pigment and dark adaptation in older population with normal maculas
1 December 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
Macular pigment (MP) such as lutein, zeaxanthin and meso-zeaxanthin are highly concentrated in the fovea. They protect the retina from damage of ambient blue light via antioxidant properties. In older eyes with normal healthy retina, macular pigment optical density (MPOD)...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Sharing best practice and landmark evidence in glaucoma care
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...On Retina UK's behalf... Grant Call - Application Deadline Extension
Further to their letter of November 2024, Retina UK is extending the deadline for expressions of interest / preliminary applications to their first grant call for an award of up to £1 million. The call forms a key element of...What's trending Oct/Nov 2019
#probeyeotic #eyeballbugs #microbiome The human microbiome usually conjures up images of the gastrointestinal tract and yoghurt containing good bacteria. However, research suggests that the ocular mucosa is home to a unique microbe collection, with important immunological functional properties [1]. This...Childhood glaucoma
When a child is given a diagnosis of glaucoma, the impact upon that child and their family is enormous; equivalent to the diagnosis of a cancer [14]. This article outlines the knowledge, techniques and approaches that offer solutions to the...Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
Ocular adnexal marginal zone b-cell lymphoma
5 August 2020
| Jonathan Chan
|
EYE - Pathology, EYE - Oncology
|
conjunctiva, epidemiology, eye lids, neoplasia, orbit
This is a multicentre retrospective study of seven eye centres of 689 patients with ocular adnexal extranodal marginal zone b-cell lymphoma (OA-EMZL). The median follow-up time was 42 months and the median age was 62 years. Fifty-five percent were women;...
